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Abstract
Objective Cerebral perfusion analysis based on arterial spin
labeling (ASL) MRI has been proposed as an alternative to
FDG-PET in patients with neurodegenerative disease. Z-maps
show normal distribution values relating an image to a
database of controls. They are routinely used for FDG-PET
to demonstrate disease-specific patterns of hypometabolism at
the individual level. This study aimed to compare the perfor-
mance of Z-maps based on ASL to FDG-PET.
Methods Data were combined from two separate sites,
each cohort consisting of patients with Alzheimer’s dis-
ease (n = 18 + 7), frontotemporal dementia (n = 12 + 8)
and controls (n = 9 + 29). Subjects underwent pseudocon-
tinuous ASL and FDG-PET. Z-maps were created for each
subject and modality. Four experienced physicians visual-
ly assessed the 166 Z-maps in random order, blinded to
modality and diagnosis.
Results Discrimination of patients versus controls using ASL-
based Z-maps yielded high specificity (84%) and positive pre-
dictive value (80%), but significantly lower sensitivity com-
pared to FDG-PET-based Z-maps (53% vs. 96%, p < 0.001).
Among true-positive cases, correct diagnoses were made in
76% (ASL) and 84% (FDG-PET) (p = 0.168).
Conclusion ASL-based Z-maps can be used for visual assess-
ment of neurodegenerative dementia with high specificity and
positive predictive value, but with inferior sensitivity com-
pared to FDG-PET.
Key points
• ASL-based Z-maps yielded high specificity and positive pre-
dictive value in neurodegenerative dementia.
• ASL-based Z-maps had significantly lower sensitivity com-
pared to FDG-PET-based Z-maps.
• FDG-PET might be reserved for ASL-negative cases where
clinical suspicion persists.
• Findings were similar at two study sites.
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Introduction
The prevalence of dementia is rapidly increasing, and the cur-
rent prognosis is that 131.5 million individuals will be afflicted
by 2050 [1], creating a great need for effective clinical diag-
nostic methods with high availability. Disease-modifying phar-
maceutical agents may become available in the near future,
which will increase the incentive for early diagnosis.
The classical role of neuroimaging in patients with
suspected dementia has been to rule out treatable causes such
as subdural haematomas and brain tumours. Modern neuro-
imaging also provides positive findings to support the clini-
cally suspected diagnosis of neurodegenerative diseases such
as Alzheimer disease’s (AD) or frontotemporal dementia
(FTD). Patterns of brain atrophy on structural MRI become
abnormal relatively late in the neurodegenerative disease pro-
cess. Functional changes precede structural changes [2], and
imaging of regional physiological parameters such as perfu-
sion or glucose metabolism increases sensitivity and enables
earlier diagnosis [3]. Glucose metabolism of the brain can be
examined with [18F]-2-fluoro-2-deoxy-D-glucose (FDG)
PET, which has proved to be a robust method for detecting
patterns of regional deficits [4, 5].
Recently, cerebral perfusion analysis based on the MRI se-
quence arterial spin labeling (ASL) has been suggested as a
biomarker for assessing the physiological state of the brain in
patients with suspected neurodegenerative disease [6–10]. ASL
can provide quantifiable perfusionmaps in a fewminutes, with-
out injecting any radioactive material or contrast agent [11].
There is a strong association between perfusion and glucose
metabolism in the brain, and patterns of ASL hypoperfusion
have been shown to be highly similar to the patterns of
hypometabolism in patients with neurodegenerative dementia
[12–14]. If ASL can provide information similar to that obtain-
ed with FDG-PET, a fairly short MRI protocol that includes an
ASL sequence could provide both morphological and physio-
logical diagnostic information non-invasively.
Visual assessment of FDG-PET images requires a high
level of experience and can be challenging, especially for
novice readers. The images are often thresholded to show
cortical areas with statistically significantly decreased metab-
olism in the individual patient compared to a database of
healthy controls. This highlights areas with metabolism levels
at the far left end of a standardized normal distribution curve.
Such Z-score maps have been shown to improve the accuracy
of diagnosing neurodegenerative disease [3, 15], especially
for novice readers [16]. Currently, there are several commer-
cially available software packages for FDG-PET analysis that
allow Z-maps to be used in a clinical setting. These types of
software commonly apply three-dimensional stereotactic sur-
face projectionmaps (3D-SSPmaps), originally introduced by
Minoshima et al. [17].
While Z-maps are established for FDG-PET, they have
only recently begun to be explored for ASL [18]. Due to the
established perfusion-metabolism coupling in the brain, ASL-
based Z-score maps should be similar to FDG-PET-based Z-
score maps. MRI is routinely performed for imaging of neu-
rodegeneration; and adding ASL would provide functional
information in addition to the standard structural information.
Also, ASL is of particular interest in the light of emerging
specific amyloid and tau tracers for PET. Instead of
performing two PET scans in a single patient, ASL might
become a clinical biomarker of unspecific perfusion/
metabolic deficits, leaving room for a specific amyloid or
tau PET tracer. The aim of this study was to compare ASL-
based to FDG-PET-based Z-score maps in patients with neu-
rodegenerative dementia, using visual assessment.
Materials and methods
Data from two cohorts were collected from separate study
sites, one in Amsterdam, The Netherlands, and one in
Uppsala, Sweden. Each cohort consisted of patients with a
clinical diagnosis of either AD or FTD, and a control group.
All subjects underwent MRI including a T1-weighted mor-
phological sequence and a pseudocontinuous ASL perfusion
sequence. On separate occasions within 6 months, all subjects
underwent FDG-PET of the brain.
The Amsterdam patient cohort was enrolled from the VU
University Medical Centre outpatient memory clinic. Prior to
inclusion, the patients had received clinical probability diagno-
ses after standardized dementia work-up including medical his-
tory, extensive neuropsychological assessment, physical exami-
nation, blood tests, lumbar puncture and neuroimaging. All pa-
tients fulfilled criteria for clinical diagnosis of either AD [19] or
behavioural variant FTD [20]. The Amsterdam control group
was recruited from subjects with subjective memory complaints
without verified cognitive or relevant psychiatric disorders.
Controls underwent standardized dementia screening, had clin-
ical assessments within normal range [14] and were selected to
have normal CSF-aβ1-42 to exclude preclinical AD.
The Uppsala patient cohort was enrolled from the Uppsala
University Hospital memory clinic. Prior to inclusion, the pa-
tients had received clinical probability diagnoses after stan-
dardized dementia work-up including medical history, neuro-
psychological assessment, physical examination, blood tests
and neuroimaging. All patients fulfilled criteria for clinical
diagnosis of AD [19], behavioural variant FTD [20] or
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semantic dementia [21]. The Uppsala control group was re-
cruited through public advertising. The controls were
interviewed and examined to rule out cognitive and relevant
neurological and psychiatric pathology, and had clinical as-
sessments within the normal range [22].
In total, 45 patients (25 AD and 20 FTD) and 38 controls
were included (total n = 83). The study was approved by the
local Medical Ethics Review Committees at the respective
sites, and all subjects provided written informed consent.
MRI protocol
All subjects were scanned using a 3T MRI scanner with an 8-
channel head coil (Amsterdam: Signa HDxt; Uppsala:
Achieva) with a protocol that included a 3D T1-weighted
gradient echo sequence and pseudo-continuous ASL. In
Amsterdam, the ASL pulse-sequence employed a 3D FSE
readout with background suppression; post-label delay =
2.0 s; TR = 9 ms; TE = 4.8 s; spiral readout with 8 arms ×
512 samples; 36 × 5.0 mm axial slices; 3.2 × 3.2 mm2 in-
plane resolution; reconstructed pixel size = 1.7 × 1.7 mm2. In
Uppsala the ASL pulse-sequence used a 2DGRE readout with
background suppression: TR = 4,100 ms, TE = 14ms, FOV =
230 × 230 mm, pixel size = 2.75 × 2.75 mm, 30 dynamic
scans, 20 slices of 5 mm, flip angle 90°. The labeling duration
was 1.65 s, and post-labeling delay 1.6 s. The multi-slice 2D
imaging readout leads to an effective delay of 1.6 s for the first
(inferior) slice, which increases to 2.3 s for the last acquired
(superior) slice.
Acquisition time was approximately 4 min at both sites. No
vascular gradient was used.
FDG-PET protocol
On subsequent occasions (mean interval 73 days), the subjects
underwent PET examinations after injection of 18F-FDG
(FDG). The Amsterdam protocol included a 15-min scan
starting 45 min after injection of 2.31 MBq/kg FDG (average
dose 187 MBq), using a Gemini TF 64 PET-CT or ECAT
Exact HR+ PET scanner (13 patients + three controls, and 17
patients + seven controls, respectively).
The Uppsala protocol included a 10-min scan starting
35 min after injection of 3 MBq/kg FDG (average dose
236 MBq), using a Discovery ST PET/CT scanner on all pa-
tients and 24 controls. Five of the controls were scanned on an
ECAT Exact HR+ PET scanner.
Further details regarding the image acquisition have been
previously described for both sites [14, 22, 23].
Image post-processing
From the raw ASL data, perfusion maps were created (in
Amsterdam: directly from the scanner; in Uppsala: using
Nordic ICE version 3.0.0 Beta). The relative perfusion maps
(relCBF) were spatially normalized in a two-step procedure
using FSL (http://fsl.fmrib.ox.ac.uk/fsl). First, the individual
images were linearly spatially normalized to the individual
3DT1 using FLIRT (part of FSL). Then, the non-linear trans-
formation of the 3DT1 data toMNI space, which was obtained
using the standard SPM processing pipeline, was applied,
resulting in spatially normalized relCBF maps in MNI space.
Next, mean and standard deviation relCBF parametric maps
were calculated separately for the Amsterdam and Uppsala
data. Finally, individual Z-score maps were calculated using
the control data from each site, respectively.
The FDG-PET data from each subject was intensity nor-
malized using a whole-brain reference value, calculated as the
mean intensity of all voxels within the brain having an inten-
sity of ≥ 0.8 of the maximum. Then, Z-score maps were pro-
duced using the same principle and computing pipeline as for
the ASL images. Thus, two Z-score maps were created for
each subject using the same post-processing procedure, one
based on ASL-perfusion and one based on FDG-metabolism
(166 maps from 83 subjects).
Interface
All images were presented using nora, an in-house developed
interface software (http://www.nora-imaging.com), providing
all relevant features of a medical imaging viewer, including
sagittal, transversal and coronal views and scrolling through
the slices of all views. Thresholded Z-scores (Z-maps) were
shown as overlays in a dichromatic colour scale, overlaid on
an averaged and heavily smoothed grey scale brain image
without specific anatomical information, to avoid assessment
bias based on atrophy patterns. The Z-score thresholds used in
the overlay were 2.0 (lower) and 6.0 (upper) by default and
manually adjustable by the readers.
Blinding
The Z-maps of patients and controls from both modalities
were presented randomly and blinded with regard to diagnosis
and modality used to construct the image. The readers neither
had access to other images such as original PET or MRI im-
ages nor to any clinical information.
Instruction tutorial
Prior to assessments, an instruction tutorial was available to
the readers, including typical cases of AD and FTD. These
additional images had been post-processed in the same way as
the 83 subjects included in the study, and were presented in the
same interface, with instructions and comments on how to
conduct the assessments. An overview publication on deficit
patterns was also added [4]. The purpose was to familiarize
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the readers with the graphical appearance of the current inter-
face and to promote a common assessment strategy.
Reading
Four experienced readers with specific interest in dementia im-
aging visually assessed and rated all images, two nuclear med-
icine physicians (NT, TD) and two neuroradiologists (KE, FB).
The nuclear medicine trained readers had 10 and >20 years of
experience of evaluation of dementia images, respectively, and
the neuroradiologists had 11 and >20 years, respectively. Each
reader assessed each Z-map and classified it as either a healthy
control or patient, with a confidence level (range 0–4)
representing how convincing the control/patient discrimination
was. For images rated as pathological, the readers also made
differential diagnostic decisions between AD and FTD.
Statistical methods
Contingency tables were constructed with kappa values and
Chi-squared tests. Proportion tests were used to compare the
performance results listed in Tables 3 and 4. Inter-reader
agreement per modality was evaluated pairwise for all readers
using Cohen’s kappa and collectively for all readers using
Fleiss’ kappa.Wilcoxon’s matched pairs test was used to com-
pare the confidence levels. Graph production and statistical
calculations were made using Dell Statistica, version 13, and
IBM SPSS, version 23.
Results
The Amsterdam patient cohort contained 18 patients with AD
and 12 patients with FTD (n = 30, mean age 62.8 years), and
the control group contained ten subjects (mean age 56.6 years).
In one case, the spatial registration proved insufficient during
post-processing, and this case was excluded from further
analysis.
TheUppsala patient cohort contained seven patients with AD
and eight with FTD (n = 15, mean age 66.7), and the control
group contained 29 healthy individuals age-matched to the pa-
tients (mean age 67.8). In two healthy controls, the time between
MRI and PET exceeded 6 months. In those cases the inclusion
procedure, including interview, Mini-Mental State Examination
(MMSE) and neurological examination, was subsequently re-
peated to ensure unchanged neurological and cognitive status.
Characteristics of the patients and controls are provided
in Table 1.
Representative subjects are shown in Fig. 1, with the im-
ages from separate sites shown pairwise, and ASL-based and
FDG-PET-based images placed columnwise for comparison.
Patient versus control distinction
In a first step, we analysed the readers’ performance in
distinguishing between patients and controls during assess-
ments. Contingency tables of distinctions for all assessments
are shown by modality in Table 2. Performance results and
comparisons are listed in Table 3.
For ASL-based maps, kappa values for pairwise inter-
reader agreement were 0.71, 0.70, 0.67, 0.54, 0.54 and 0.40,
and the total kappa for all readers was 0.58. For FDG-PET-
based maps, kappa values for pairwise agreement were 0.51,
0.51, 0.39, 0.37, 0.36 and 0.33, and the total kappa for all
readers was 0.38. No systematic differences were identified
between the readers with a background in nuclear medicine
compared to the neuroradiologists.
As shown in Table 3, ASL-based images yielded higher
specificity, positive predictive value, inter-reader agree-
ment and confidence scores. FDG-based images yielded
higher sensitivity, negative predictive value and accuracy.
However, the FDG-based images of controls contained a
large number of uncertain cases. Exclusion of uncertain
cases resulted in modest improvements in both modalities,
shown in parentheses in the tables.
Table 1 Subject characteristics
by centre and diagnostic category.
In total, 45 patients and 38
controls were included
Amsterdam Uppsala
AD
N = 18
FTD
N = 12
Controls
N = 9
AD
N = 7
FTD
N = 8
Controls
N = 29
Age, years (SD) 64 (8) 61 (8) 57 (9) 65 (9) 68 (10) 68 (7)
Gender (% male) 61% 42% 89% 57% 61% 52%
MMSE (SD) 24 (4) 24 (4) 27 (3) 24 (4) 28 (2) 29 (1)
Scan interval in months (SD) 2.1 (1) 2.2 (2) 1.4 (2) 1.9 (3) 2.6 (2) 2.9 (5)
AD Alzheimer’s disease, FTD frontotemporal dementia, ASL arterial spin labeling, PET positron emission to-
mography, MMSEMini-Mental State Examination,
Mean values and standard deviations (SDs) are given
Scan interval is in months and represents the time between the ASL scan and the FDG-PET scan
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Diagnosis-specific analysis
In a second step, we analysed the readers’ performance in
assessing the correct differential diagnosis (AD vs. FTD).
Results are provided in Table 4.
The patient groups were examined separately. ASL yielded
a higher rate of correct differential diagnosis in AD cases
compared to FTD cases (89% vs. 56%, p < 0.001). FDG-
PET yielded similar results between patient groups (Table 3).
The cohorts were also examined separately. The rate of
false-positive findings was higher in ASL images from the
Uppsala cohort compared to the Amsterdam cohort (20%
vs. 3%, p = 0.015). This difference was not evident in
FDG-PET-based images (47% vs. 40%, p = 0.599). In oth-
er respects, the cohorts were similar, with no other differ-
ence reaching statistical significance.The results are pro-
vided in Table 5.
A sample healthy control with false-positive findings is
shown in Fig. 2. Both the ASL-based and FDG-PET-based
Z-maps from this subject show false-positive patterns repre-
sentative for the respective modality in this study.
A representative discordant patient is shown in Fig. 3.
The ASL-based map of this AD patient was assessed as
false negative by three readers, while the FDG-PET-based
map was correctly diagnosed by all readers. Several false-
negative ASL cases in the study had such disease-typical
deficit patterns that were less evident, or not at all evident,
with the default settings, but could be revealed by indi-
vidually adjusting the Z-score threshold.
Discussion
Themain finding in this study is that ASL-based Z-maps can be
visually assessed with high specificity and positive predictive
value in patients with AD and FTD. Sensitivity and accuracy
were lower than in corresponding FDG-PET-based images.
ASL can easily be added to the routinely performed MRI
Table 2 Contingency table of patient/control distinction for all
assessments (four raters × 83 maps), by modality. One data point was lost
from the FDG-PET data during extraction (n = 331 instead of 332)
ASL-based FDG-PET-based
Image rated as: Controls Patients Controls Patients
Normal 128 84 82 8
Pathological 24 96 69 172
n: 332 n: 331
K: 0.364 K: 0.515
p: < 0.001 p: < 0.001
K represents the Cohen kappa value of each contingency table
Fig. 1 Representative subjects.
Sample images from one control,
one AD patient and one FTD
patient from each site. Images are
shown pairwise from the separate
sites. ASL- and FDG-based
images are shown in separate
columns. The leftmost image in
each box is an axial slice from the
original image shown in a
manually windowed Osirix
rainbow scale. The middle and
rightmost images in each box are
axial and sagittal Z-maps created
from the respectivemodality, with
thresholded overlays shown in a
dichromatic colour scale with the
default lower and upper Z-score
thresholds of 2.0 (red) and 6.0
(yellow). AD Alzheimer’s
disease, FTD frontotemporal
dementia, ASL arterial spin
labeling, Ams Amsterdam, Upp
Uppsala
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protocol of a dementia-workup, and creating Z-maps consti-
tutes a relatively minor additional effort. The high specificity
and positive predictive value of ASL indicates that an abnormal
finding can provide a specific diagnosis with little additional
effort. If ASL is negative or inconclusive but the clinical
suspicion persists, the addition of FDG-PET could be consid-
ered due to its excellent sensitivity and superior accuracy.
The lower sensitivity of ASL in this study may imply
that regional perfusion decrease is evident at a later stage
than regional decrease of glucose metabolism. Since the
ASL scans were acquired prior to FDG-PET, there is a
theoretical possibility that disease progression between
scans contributed to the difference, but this was consid-
ered unlikely. Sensitivity is also associated with the Z-
score threshold, as discussed below.
ASL was more efficient in diagnosing AD cases compared
to FTD, whereas FDG-PET showed no difference between
patient groups. This could possibly represent a more disease-
specific change of perfusion in AD than in FTD, as previously
described [24]. This issue should be addressed in a larger
study with a specific approach. Differential diagnosing was
less robust in ASL than in FDG-PET.
When study sites were compared, a higher rate of false-
positive findings was found among the ASL images in the
Uppsala cohort. This could be caused by a higher mean age
in the Uppsala control group, or by methodological differ-
ences between the ASL protocols at the two sites [11].
The rate of uncertain cases and false-positive results
was higher in FDG-based images of healthy controls, as-
sociated with method-dependent false-positive Z-scores,
as shown in Fig. 2. As a consequence, the FDG-based
Z-maps showed poor specificity and inter-reader agree-
ment. This is not in agreement with previous FDG-PET
studies based on the 3D-SSP method [3, 25] and presum-
ably depends on methodological differences – 3D-SSP
maps are based on specific post-processing operations
not used in this study. Instead, the current study used a
voxel-wise comparison of all voxels after spatial normal-
ization to directly compare ASL versus FDG-PET. Thus,
the method used in this study is more vulnerable to reg-
istration mismatch and partial volume effects. 3D-SSP
tools were not used because the available software pack-
ages are not constructed and optimized for ASL-MRI,
Table 4 Differential diagnosis
performance results by modality Measure ASL FDG-PET p value
Correct differential diagnosis 76% (80%) 84% (86%) 0.168 1)
Unanimous differential diagnosis 24% 60% <0.001 2)
Correct diagnosis rate in AD cases 89% 82% 0.482 3)
Correct diagnosis rate in FTD cases 56% 87% 0.030 3)
Values that were significantly higher than the corresponding value from the other modality have been marked in
bold. The performance results in parentheses show the results after exclusion of uncertain cases
1 Rate of correct differential diagnosis among true positive cases
2 All readers gave correct differential diagnosis
3 Rate of correct diagnosis among true positive cases
AD Alzheimer’s disease, FTD frontotemporal dementia, ASL arterial spin labeling, PET positron emission
tomography
Table 3 Patient/control performance results by modality
Measure ASL FDG-PET p value
Sensitivity 53% (53%) 96% (99%) <0.001
Specificity 84% (85%) 54% (54%) <0.001
Negative predictive value 60% (61%) 91% (97%) <0.001
Positive predictive value 80% (81%) 71% (76%) 0.007
Accuracy 68% (68%) 77% (80%) 0.008
Uncertain cases, controls 7% 25% <0.001 1)
Uncertain cases, patients 8% 7% 0.741 1)
Inter-reader agreement 0.58 0.38 N/A 2)
Unanimous distinction 66% 57% 0.235 3)
Unanimous correct distinction 49% 52% 0.607 4)
Distinction of AD cases 57% 95% 0.002 5)
Distinction of FTD cases 49% 96% <0.001 5)
Higher confidence score 125 87 <0.001 6)
Values that were significantly higher than the corresponding value from
the other modality have been marked in bold. The performance results in
parentheses show the results after exclusion of uncertain cases
1 Rate of cases with confidence level <2
2 Fleiss’ kappa describing inter-reader agreement for all readers
collectively
3 ‘Unanimous distinction’ means that all readers agreed on the patient/
control distinction
4 All readers agreed on the correct distinction
5 The rate of patients from each diagnosis category that were correctly
identified as patients
6 The number of instances with higher confidence score than the corre-
sponding image from the other modality, examined with Wilcoxon
matched pairs
ADAlzheimer’s disease, FTD frontotemporal dementia, ASL arterial spin
labeling, PET positron emission tomography
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which might bias the results. The authors would like to
emphasize that the current method was intended for direct
comparison between modalities only, not for clinical im-
plementation. As a next step, assessing 3D-SSP analysis
of ASL would be an interesting pursuit, with potential for
clinical implementation [18].
Evaluation of ASL perfusion has several potential pit-
falls such as artefacts and variability [26–28]. The quan-
tification models currently available rely partly on ap-
proximations and assumptions, and development is on-
going [29, 30]. There is considerable variance in cerebral
perfusion levels in healthy controls, which makes cut-off
values between normal and pathological perfusion diffi-
cult to establish [31–33]. The interindividual variance in
ASL perfusion is large compared to the variance of SUV
ratios in FDG-PET [31–33]. This is an important issue
when comparing an individual subject to a control group
of limited size.
While corrections for partial volume effects can be
beneficial for optimizing the quantitative aspect of ASL,
they are currently not used clinically in a standardized
manner, and were not used in this study. In the clinical
situation, the diagnostic physician can estimate the degree
of partial volume effects by comparing the ASL scan to
the structural images.
As shown in Fig. 3, the default threshold was not
always suitable for the ASL-based images. In certain
cases, adjusting the threshold revealed a distinct
Fig. 2 Healthy control with false-positive findings. Both the ASL-based
and FDG-PET-based Z-score maps show false-positive Z-score patterns
representative for the respective modality in this study. The clusters at the
junction between grey and white matter in the lower row were present in
several of the FDG-PET images of healthy controls, contributing to the
number of uncertain cases, false-positive assessments and limited inter-
rater agreement. The ASL-based map from this particular healthy control
was read as AD by one reader, and the FDG-PET-based images as AD by
two readers and FTD by one reader. The Z-maps are shown with
thresholded overlays in a dichromatic colour scale with the default lower
and upper Z-score thresholds of 2.0 (red) and 6.0 (yellow). ASL arterial
spin labeling, FTD frontotemporal dementia, PET positron emission
tomography, AD Alzheimer’s disease
Table 5 Comparison between
sites. There was a significantly
higher false-positive rate in
Uppsala controls compared to
Amsterdam controls (p = 0.015).
In other respects, results were
similar between sites
Measure Modality Amsterdam Uppsala p value
False-positive rate ASL 3% 20% 0.015
FDG-PET 40% 47% 0.60
Distinction of AD cases ASL 58% 54% 0.67
FDG-PET 94% 96% 0.68
Distinction of FTD cases ASL 46% 53% 0.52
FDG-PET 96% 97% 0.81
Correct diagnosis rate in AD ASL 86% 100% 0.12
FDG-PET 81% 85% 0.62
Correct diagnosis rate in FTD ASL 59% 53% 0.70
FDG-PET 87% 87% 0.98
AD Alzheimer’s disease, FTD frontotemporal dementia, ASL arterial spin labelling, PET positron emission
tomography
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disease-typical pattern. The readers reported mostly using
the default settings. Optimal thresholding for each subject
was not systematically explored. This could be an inter-
esting objective for a separate study with a different de-
sign. A larger normal database, preferably with subsam-
pling of age and gender, would facilitate the distinction
between normal and pathological. Plausibly, improved
ASL sequences in the near future can provide more ro-
bust data with less variance.
Differences in scanning protocols between the sites
could be a limitation due to possible bias, but was kept
to a minimum by using the controls from each site as
separate reference groups when constructing the Z-maps.
The most important difference was the use of 2D versus
3D readout of the ASL-scans. Previous comparisons be-
tween 2D and 3D ASL protocols (similar to those used
in this study) have shown regional differences in CBF,
but similar total grey matter CBF, as well as similar
coefficients of variance [34]. Multisite ASL studies have
been considered problematic due to site dependence [11,
35]. The highly similar findings between sites in this
study suggest that valid results are possible with differ-
ent ASL protocols.
Another limitation is the sizes of the cohorts and con-
trol groups. The ideal control group would be larger and
perfectly matched to the patients in gender and age, or
large enough to sub-sample accordingly. Using subjects
with subjective cognitive symptoms as controls, as done
in the Amsterdam cohort, could be a potential confound-
ing factor, but the rate of false positives was lower com-
pared to the Uppsala cohort. The patient groups from the
respective sites had slightly different compositions
(Table 1), but the potential impact on the results was con-
sidered minor.
Conclusions
ASL perfusion-based Z-score maps can be used as a diagnostic
tool in patients with suspected neurodegenerative disease. In
the current study, ASL provided high specificity and positive
predictive value as a stand-alone sequence. In future studies,
the performance can potentially be improved with implemen-
tation in a 3D-SSP software tool, and combined with morpho-
logical MRI data. FDG-PET might be reserved for those cases
where ASL is negative and high clinical suspicion persists.
Fig. 3 Representative discordant case. The ASL-based image of this AD
case (Age: 67 years, MMSE: 25) was assessed as false negative by three
of four readers, while the corresponding FDG-PET image was
unanimously correctly diagnosed. The top row shows the ASL-based
image with the default Z-score thresholds (lower 2.0, upper 6.0). The
middle row shows the same image after threshold adjustment (0.77,
1.87). The bottom row shows the FDG-PET-based images of the same
subject, with default threshold settings (2.0, 6.0). This is a representative
case of a disease-typical deficit pattern evident on ASL-based images
only after individually adjusting the threshold. Images are shown in a
dichromatic colour scale ranging from red (lower threshold) to yellow
(upper threshold). ASL arterial spin labeling, AD Alzheimer’s disease,
MMSE Mini-Mental State Examination, FTD frontotemporal dementia,
PET positron emission tomography
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